Literature DB >> 17971712

The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy.

Brian Wells Pence1, Jan Ostermann, Virender Kumar, Kathryn Whetten, Nathan Thielman, Michael J Mugavero.   

Abstract

BACKGROUND: Expanded access to antiretroviral therapy (ART) has produced dramatic reductions in HIV-associated morbidity and mortality. Disparities in access to and benefit from ART have been observed by race, gender, and mental health status, however.
METHODS: From 2001 to 2002, 611 HIV-positive patients were consecutively recruited from 5 southeastern US states and followed for 3 years. We evaluated demographic and psychosocial predictors of probability of receiving ART among all those eligible for ART (on ART, CD4 <350 cells/mm3 or viral load [VL] >55,000 copies/mL in the year preceding enrollment), time to first ART discontinuation among those on ART, and time to VL >400 copies/mL among those on ART with VL <400 copies/mL at enrollment.
RESULTS: Of 611 participants, 474 consented to medical record abstraction and had known ART status at enrollment; 81% (385 of 474) of all participants and 89% (385 of 435) of ART-eligible participants were receiving ART at enrollment. In multivariable analyses, ART receipt was associated with greater age (adjusted odds ratio = 1.92 per 10 years, 95% confidence interval: 1.23 to 3.01), fewer recent stressful life events (odds ratio = 0.68, 95% confidence interval: 0.51 to 0.92), less alcohol use (odds ratio = 0.64, 95% confidence interval: 0.46 to 0.90), and greater perceived self-efficacy (OR = 2.82, 95% confidence interval: 1.41 to 5.62). No psychosocial characteristics were associated with ART discontinuation or virologic failure. No racial/ethnic or gender disparities were observed in ART receipt; however, minority racial/ethnic groups were faster to discontinue ART (adjusted hazard ratio = 2.44, 95% confidence interval: 1.33 to 4.49) and experience virologic failure (adjusted hazard ratio = 2.01, 95% confidence interval: 1.09 to 3.71).
CONCLUSIONS: Patients with unfavorable psychosocial profiles were less likely to be on ART, perhaps attributable to providers' or patients' expectations of readiness. Psychosocial characteristics were not associated with ART discontinuation or virologic failure, however, possibly reflecting the selection process involved in who initiates ART. Racial disparities in ART discontinuation and virologic failure merit further attention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17971712     DOI: 10.1097/QAI.0b013e31815ace7e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  45 in total

1.  Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care.

Authors:  Jennifer N Sayles; Jacqueline Rurangirwa; Min Kim; Janni Kinsler; Rangell Oruga; Mike Janson
Journal:  AIDS Patient Care STDS       Date:  2012-07-09       Impact factor: 5.078

2.  Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study.

Authors:  Jane M Simoni; David Huh; Ira B Wilson; Jie Shen; Kathy Goggin; Nancy R Reynolds; Robert H Remien; Marc I Rosen; David R Bangsberg; Honghu Liu
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

Review 3.  Healthy Aging in Older Women Living with HIV Infection: a Systematic Review of Psychosocial Factors.

Authors:  Anna A Rubtsova; Mirjam-Colette Kempf; Tonya N Taylor; Deborah Konkle-Parker; Gina M Wingood; Marcia McDonnell Holstad
Journal:  Curr HIV/AIDS Rep       Date:  2017-02       Impact factor: 5.071

4.  Race, Relationships and Trust in Providers among Black Patients with HIV/AIDS.

Authors:  Tara R Earl; Mary Catherine Beach; Margaret Lombe; P Todd Korthuis; Victoria L Sharp; Jonathan A Cohn; Richard D Moore; Somnath Saha
Journal:  Soc Work Res       Date:  2013-09-01

5.  Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.

Authors:  Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

6.  Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.

Authors:  Alison J Hughes; Christine L Mattson; Susan Scheer; Linda Beer; Jacek Skarbinski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

7.  Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

Authors:  Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2013-09-17       Impact factor: 9.079

8.  Racial disparities in HIV virologic failure: do missed visits matter?

Authors:  Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan Davies; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

9.  The therapeutic implications of timely linkage and early retention in HIV care.

Authors:  Kimberly B Ulett; James H Willig; Hui-Yi Lin; Justin S Routman; Sarah Abroms; Jeroan Allison; Ashlee Chatham; James L Raper; Michael S Saag; Michael J Mugavero
Journal:  AIDS Patient Care STDS       Date:  2009-01       Impact factor: 5.078

10.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.